Proteinuria Treatment Market Share

Global Proteinuria Treatment Market Overview

Proteinuria Treatment Market size was valued at USD 1.90 billion in 2022. The Proteinuria Treatment Market industry is projected to grow from USD 2.05 billion in 2023 to USD 4.11 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.17% during the forecast period (2023 - 2032).

Rising prevalence of kidney disease worldwide and increasing development of innovative drugs are propelling the growth of the market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Proteinuria Treatment Market Trends

• Increasing incidences of infectious diseases

The prevalence of kidney disease is on the rise worldwide due to factors such as increasing incidence of diabetes and rising obesity rates. As per the World Kidney Day 2022 Campaign, 1 in 10 people worldwide was diagnosed with CKD, and further, it has been estimated that kidney disease-related mortality is persistently increasing and that by 2040, it will be the 5th leading cause of death globally. Moreover, diabetes is a major risk factor for proteinuria. In people with diabetes, high blood sugar levels can damage the kidneys and cause them to leak protein. According to the International Diabetes Federation Atlas 2022, there were approximately 476 indigenous people suffering from diabetes across 90 countries worldwide. Furthermore, people who are obese are more likely to have proteinuria than people who are not obese. This is because obesity can lead to high blood pressure, inflammation, and stress on the kidneys, which may damage the kidneys. The World Health Organization has reported that more than 1 billion people were diagnosed with obesity worldwide in 2022.

Therefore, increasing incidences of kidney failure or mild kidney diseases are boosting the growth of the Proteinuria Treatment Market.

Proteinuria Treatment Market Segment Insights:

Proteinuria Treatment Market Disease Type Insights

The Proteinuria Treatment Market is segmented, based on disease type, into transient proteinuria, orthostatic proteinuria, and persistent proteinuria. The transient proteinuria segment held the majority share of the market, with a market share of approximately 35–45% in 2022 and persistent proteinuria is the fastest-growing segment during the forecast year. Persistent proteinuria is characterized by the presence of excessive amounts of protein in the urine on a regular basis. It can be caused by a variety of factors, including kidney disease, diabetes, and high blood pressure. It has been estimated by the World Health Organization that nearly 1.28 billion people globally have had hypertension by March 2023. Moreover, the majority of people with hypertension are living in low- and middle-income countries (LMIC).

Thus, increasing hypertension cases among the population worldwide increases the chances of persistent proteinuria, which fuels disease-type segment growth.

Proteinuria Treatment Market Drug Class Insights

The Proteinuria Treatment Market segmentation, based on drug class, includes angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), dipeptidyl peptidase (DPP) IV inhibitors, aldosterone antagonists, selective use in proteinuria, diuretics, and others. The angiotensin-converting enzyme (ACE) inhibitors segment includes benazepril, captopril, enalapril, fosinopril, and others. The angiotensin-converting enzyme (ACE) inhibitors segment dominated the market in the base year, i.e., 2022, and angiotensin receptor blockers segment is the fastest-growing segment during the forecast period, 2023–2032. This is because it has been found through secondary research that angiotensin-converting enzyme (ACE) inhibitors are highly effective in treating proteinuria by relaxing blood vessels.

FIGURE 2: PROTEINURIA TREATMENT MARKET, BY DRUG CLASS, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Proteinuria Treatment Market Route of Administration Insights

On the basis of route of administration, the Proteinuria Treatment Market has been segmented into oral and intravenous. The oral segment held the largest market share in 2022, and intravenous is the fastest-growing segment during the forecast period. This is due to the innovative drug product launch and approval for oral administration to treat proteinuria. For instance, in December 2021, Calliditas Therapeutics (Sweden) received US Food and Drug Administration approval for TARPEYO (budesonide). It is the first delayed release capsules approved for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN).

Proteinuria Treatment Market Distribution Channel Insights

Based on distribution channel, the Proteinuria Treatment Market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in the base year, i.e., 2022, and the online pharmacies segment is the fastest-growing segment during the forecast period, 2023–2032. Furthermore, the factors influencing the growth of the hospital pharmacies segment are rising incidences of diabetes, obesity, hypertension, and other kidney diseases. Moreover, the International Diabetes Federation Atlas 2021 reported that approximately 643 million people will be living with diabetes globally, in 2030 and 783 million in 2045, creating flourishing opportunities for hospital pharmacies during the forecast period. Hospital pharmacies are generally more widely available and are also the preferred mode of purchase for the end users.

Proteinuria Treatment Market Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and the rest of the world. In North America, the proteinuria treatment market held the largest market share in 2022 due to the presence of major players in the US such as Chinook Therapeutics, Inc. (US), Travere Therapeutics (US), and Pfizer, Inc. (US). In addition, the rising incidences of IgAN are fueling the North America region’s growth. As per the National Kidney Foundation, in March 2023, approximately 150,000 people in the US were diagnosed with IgAN, which is a rare kidney disease (RKD) that may lead to kidney failure due to glomerular disease.

Hence, the presence of major players in the region and increasing incidences of IgAN, a rare disease, are fostering the growth of the North American proteinuria treatment market.

Further, the major countries studied are: The US, Canada, France, Germany, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

FIGURE 3: PROTEINURIA TREATMENT MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

The European proteinuria treatment market accounted for the second-largest market share due to growing incidences of chronic kidney diseases. The European Union announced in February 2022 that approximately 100 million people will suffer from chronic kidney disease (CKD) in Europe by 2040, which is a lucrative opportunity for the proteinuria treatment market. Proteinuria is found in all CKD patients because CKD patients’ kidneys are unable to filter protein due to damage to the kidney arteries. Furthermore, the Germany proteinuria treatment market held the largest market in 2022, and the UK proteinuria treatment market is projected to be the fastest-growing market in the Europe region.

The Asia-Pacific proteinuria treatment market is the fastest-growing region from 2023 to 2032, owing to the growing incidence of kidney diseases and the rising geriatric population in the region. In March 2022, the George Institute revealed that major cases of CKD have been found in China and India due to the presence of a larger population and increased cases of diabetes in the eastern, southern, and south-eastern regions of Asia. Moreover, as per Johns Hopkins University (US), there is a 50% chance of having CKD among 75-year-old people. Additionally, through secondary research, it has been found that the geriatric population is living in Asian countries, mostly in East and Northeast Asia, with approximately 329 million in 2022. Furthermore, the China proteinuria treatment market accounted for the largest market share in 2022, and the India proteinuria treatment market is projected to be the fastest-growing market in the Asia-Pacific region.

Proteinuria Treatment Market Key Market Players & Competitive Insights

Major market players are extensively spending on R&D to extend their service offering, which contributes to the growth of the proteinuria treatment market. Moreover market participants are also growing their worldwide footprint through various strategic initiatives such as the launch of a new product, contractual agreements, mergers and acquisitions, investments, and collaboration with other market participants.

Travere Therapeutics (US) is a biopharmaceutical company focused on identifying, developing, acquiring, and commercializing innovative therapies to improve the lives of patients with rare diseases. It has a presence in North America and Europe. Furthermore, in February 2023, Travere Therapeutics (US) received US Food and Drug Administration approval for FILSPARI. It is the first and only non-immunosuppressive therapy approved for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN).  

Key Companies in the Proteinuria Treatment Market includes.

• Travere Therapeutics (US)


• Chinook Therapeutics, Inc. (US)


• Novartis AG (Switzerland)


• Alnylam Pharmaceuticals, Inc. (US)


• AstraZeneca PLC (UK)


• Sanofi S.A. (France)


• Calliditas Therapeutics AB (Sweden)


• Eli Lilly and Company (US)


• Bayer AG (Germany)


• Pfizer, Inc. (US)


• Others

Proteinuria Treatment Market Industry Developments

• May 2023: Chinook Therapeutics, Inc. (US) announced that Atrasentan is a potent and selective endothelin A (ETA) receptor antagonist that has potential therapeutic benefit in multiple chronic kidney diseases by reducing proteinuria.


• February 2023: Travere Therapeutics (US) received US Food and Drug Administration approval for FILSPARI. It is the first and only non-immunosuppressive therapy approved for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN).


• June 2021: Novartis AG (Switzerland) announced that iptacopan met the primary endpoint of the phase II study in the rare kidney disease IgA nephropathy (IgAN). The iptacopan in IgAN demonstrated an effective and clinically meaningful reduction of proteinuria.


• December 2021, Calliditas Therapeutics (Sweden) received US Food and Drug Administration approval for TARPEYO (budesonide). It is the first delayed release capsules approved for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN).

Proteinuria Treatment Market Segmentation

Proteinuria Treatment Market Disease Type Outlook

• Transient Proteinuria


• Orthostatic Proteinuria


• Persistent Proteinuria

Proteinuria Treatment Market Drug Class Outlook

• Angiotensin-converting Enzyme (ACE) Inhibitors
  
  
  
  • Benazepril
  
  
  • Captopril
  
  
  • Enalapril
  
  
  • Fosinopril
  
  
  • Others
  
  
  
  


• Angiotensin Receptor Blockers (ARBs)


• Dipeptidyl Peptidase (DPP) IV Inhibitors


• Aldosterone Antagonists, Selective use in proteinuria


• Diuretics


• Others

Proteinuria Treatment Market Route of Administration Outlook

• Oral


• Intravenous

Proteinuria Treatment Market Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies

Proteinuria Treatment Market Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America